Cheng Cui
Impact in
- Infectious Diseases top 1%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Neurology top 2%
- Long-Term Effects of COVID-19
Papers in
-
- Antibiotics Pharmacokinetics and Efficacy 8
- Pharmacogenetics and Drug Metabolism 4
Cheng Cui
40 papers receiving 2.1k citations
Hit Papers
Peers
Comparison fields: 5 of 132
- Infectious Diseases 1.5k
- Neurology 549
- Ophthalmology 171
- Pharmacology 154
- Computational Theory and Mathematics 179
Countries citing papers authored by Cheng Cui
This map shows the geographic impact of Cheng Cui's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cheng Cui with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cheng Cui more than expected).
Fields of papers citing papers by Cheng Cui
This network shows the impact of papers produced by Cheng Cui. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cheng Cui. The network helps show where Cheng Cui may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Cheng Cui, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2025 | 0 | |
| 3 | 2025 | 1 | |
| 4 | 2025 | 0 | |
| 5 | 2025 | 0 | |
| 6 | 2024 | 1 | |
| 7 | 2024 | 2 | |
| 8 | 2023 | 6 | |
| 9 | 2023 | 2 | |
| 10 | 2023 | 5 | |
| 11 | 2023 | 2 | |
| 12 | 2023 | 4 | |
| 13 | 2023 | 1 | |
| 14 | 2023 | 8 | |
| 15 | 2022 | 16 | |
| 16 | In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Hit paper breakdown → | 2020 | 1855 |
| 17 | 2020 | 3 | |
| 18 | 2018 | 6 | |
| 19 | 2017 | 9 | |
| 20 | 2012 | 1 |
About Cheng Cui
Cheng Cui is a scholar working on Geriatrics and Gerontology, Pharmacology, Pharmacology, Endocrinology, Diabetes and Metabolism and Nutrition and Dietetics, having authored 44 papers that have together received 2.2k indexed citations. Recurring topics across this work include Antibiotics Pharmacokinetics and Efficacy (8 papers), COVID-19 Clinical Research Studies (6 papers), Diabetes Treatment and Management (6 papers), Pharmacogenetics and Drug Metabolism (4 papers), Drug Transport and Resistance Mechanisms (4 papers), Atrial Fibrillation Management and Outcomes (3 papers), Diabetes Management and Research (3 papers) and Antiplatelet Therapy and Cardiovascular Diseases (3 papers). The work is most often cited by research in Infectious Diseases (1.5k citations), Neurology (549 citations), Ophthalmology (171 citations), Pharmacology (154 citations) and Computational Theory and Mathematics (179 citations). Cheng Cui has collaborated with scholars based in China, United Kingdom and Pakistan. Frequent co-authors include Dongyang Liu, Haiyan Li, Xueting Yao, Chunli Song, Baoying Huang, Miao Zhang, Erdan Dong, Li Zhao, Fei Ye and Xu Liu. Their work appears in journals such as Current Drug Metabolism, Frontiers in Pharmacology, Clinical Pharmacology & Therapeutics, Clinical Pharmacokinetics and Clinical Infectious Diseases.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.